1. Introducing the Challenge: The Management of Gliomas {#sec1}
=======================================================

Gliomas are the most frequent primary brain tumors in adults accounting for more than 70% of all brain neoplasms and display a group of tumors with different features regarding morphology, genetic and epigenetic aberrations, and response to therapy \[[@B1]\]. An additional relevant feature of gliomas represents its great tendency to infiltrate into adjacent normal brain tissue. The outer border of gliomas, as observed by T1-weighted magnet resonance imaging (MRI), does not delineate the true dimension of the tumor. Moreover, tumor cells diffusely invade the normal brain and can be detected far beyond rendering this condition incurable by combined surgery, radio, and chemotherapy ([Figure 1](#fig1){ref-type="fig"}). This is more true for glioblastoma multiforme (GBM), which accounts for about 60% of all gliomas and 12--15% of all brain tumors, and it is per se the most frequent primary brain tumor \[[@B1], [@B2]\]. It is one of the most devastating and lethal forms of human cancer despite the significant efforts that have been made to unravel its molecular basis. In Europe and North America, the incidence is three new cases per 100,000 inhabitants per year (Central Brain Tumor Registry of the United States, CBTRUS, [http://www.cbtrus.org/](http://www.cbtrus.org)). Although GBM can manifest itself at any age, it preferentially occurs in adults, with a wide peak age of incidence between 45 and 70 years \[[@B3]\].

In spite of all the progress in the fields of surgery and radiochemotherapy, including the milestone of chemotherapy with the alkylating drug temozolomide, the prognosis of GBM is still dismal \[[@B3]--[@B5]\]. Recently published meta-analyses reported that, despite multimodal therapy with gross total resection and radio- and chemotherapy with temozolomide, an improvement of only few months in median survival time (14.6 months) had been achieved compared to surgery plus radiotherapy alone (12.1 months) \[[@B6]\]. As a general rule, tumor recurrence develops after a short relapse-free period, signaling a survival time of 5--8 months \[[@B4]\].

2. Crosstalk between Genetics and Epigeneticsin Gliomas {#sec2}
=======================================================

In benign astrocytomas WHO grade II, the most common genetic alteration is mutations of the *TP53* gene in about 60% of the cases as well as mutations of the isocitrate dehydrogenase 1 (*IDH1*) gene in about 70% of the tumors \[[@B1]\]. The rates of these mutations may vary between subtypes, for instance *TP53* mutations have been observed in up to 80% of astrocytomas with gemistocytic features \[[@B7]\]. Epigenetic alterations in grade II astrocytomas are promoter hypermethylation of the DNA repair gene *MGMT*, the protocadherin-gamma subfamily A11 (*PCDH-gamma-A11*) and the tumor suppressor gene *EMP3* \[[@B8]\]. Interestingly in grade II gliomas without *TP53* mutations, epigenetic downregulation of *CDKN2A*, which regulates the *MDM2*-associated p53 degradation, is frequently observed \[[@B9]\]. In anaplastic astrocytomas WHO grade III, *TP53* and *IDH1* mutations have been observed with similar frequencies to grade II tumors. Moreover, mutations of the *RB1* gene occur in about 25% of the cases. Furthermore, the cell-cycle regulator genes *CDKN2A* and *CDKN2B* undergo commonly inactivation via genetic mutation and epigenetic silencing \[[@B10]\].

Concerning GBM, two patterns have so far been described in the pathogenesis through the gatekeeper pathway. These have different molecular profiles. Type 1 GBM typically shows inactivation of the *TP53* tumor suppressor gene but no amplification of the *EGFR* oncogene. Mutations of *p53*, mostly associated with loss of heterozygosity (LOH) in the 17p chromosome region, can be observed in GBM originating from a less malignant glioma precursor. *TP53* inactivation does not occur together with amplification of the *EGFR* oncogene, which is only identified in GBM without *TP53*mutation \[[@B1], [@B11]--[@B13]\]. More than 70% of malignant gliomas show a deregulated *TP53* pathway not only by mutation of *TP53*but also amplification of *MDM2*, homozygous deletion/mutation, or promoter hypermethylation-mediated silencing of *CDKN2A*as shown in [Figure 2](#fig2){ref-type="fig"} \[[@B10], [@B14]\].

In contrast, type 2 GBM shows overexpression or amplification of the *EGFR* without mutations of *TP53* \[[@B11], [@B15]\], and it appears de novo, that is, in patients without a less malignant precursor neoplasm such as grade II or III astrocytoma \[[@B16]\]. The former molecular data strongly pinpoint to two independent GBM pathogenetic pathways \[[@B17]\]. Moreover, *EGFR* amplification is almost always consistent with LOH in chromosome region 10q \[[@B16]\]. The tumor suppressor gene *PTEN,* mapping the 10q23 region, is mutated in approximately 30% of type 2 GBM \[[@B18]\]. Mutations in this gene have been described only in malignant gliomas and are rarely associated with *p53*mutations. Other frequent mutations in type 2 GBM affect the *CDK* cell-cycle-regulator genes. Amplification of *CDK4*and *CDK6* was observed in 15% of type 2 GBMs \[[@B10]\]. Mutations of the cell-cycle-regulator genes *CDKN2A/CDKN2B* have been observed in 40% of all GBM. Moreover, a functional loss of expression of the *CDKN2A*gene by promoter hypermethylation was found in 15% of GBM as well \[[@B19]\]. Mutations of the *IDH1*gene have been frequently observed in those GBM progressing from a less malignant precursor lesion, that is in type 1 GBM, mostly of them affecting young patients. Interestingly, these *IDH1* mutations were associated with a better outcome \[[@B20], [@B21]\].

In addition to type 1 and type 2 GBMs, there are other forms, whose molecular profiles do not identify them as belonging to either of the two classic pathways \[[@B12], [@B15], [@B22]\]. A small subgroup of these GBMs is found to harbor LOH on chromosomes 1p and 19q, which have been suspected for a long time of containing tumor suppressor genes \[[@B15], [@B23]\].

In recent years, the epigenetic pattern of gliomas has received increasingly attention and many efforts have been done to define it. Nevertheless, it is only partially devised. Global DNA hypomethylation in gliomas, affecting up to 10 million CpG dinucleotides per haploid tumor genome, actually occurs in GBM \[[@B24]\]. This phenomenon appears to be associated with malignant evolution of cells through activation of oncogenes, promotion of genomic instability, or the loss of imprinting. Moreover, the significance of hypermethylation of CpG island of gene promoters in GBM is highlighted by the observation of epigenetic-mediated inactivation of a wide variety of genes associated with tumor suppression (*RB1, VHL, EMP3*, *RASSF1A, BLU*), cell cycle regulation (*CDKN2A/CDKN2B*), DNA repair (*MGMT, hMLH1*), and tumor invasion and apoptosis (*DAPK1, TIMP3, CDH1*, the protocadherin family member *PCDH-gamma-A11, TMS1/ASC*) \[[@B25]--[@B31]\]. These epigenetic events have been described in oligodendrogliomas and ependymomas as well \[[@B32]\].

The methylation signature of gliomas is also rather associated with tumor lineage and malignancy grade. Thus, astrocytomas grades WHO II and III and GBM grade IV show different methylation status of several genes \[[@B33]\]. Even though, primary and secondary GBMs were found to differ concerning methylation of genes which was associated with decreased mRNA levels \[[@B34]\]. In this context, methylation of *MGMT* is more frequently observed in 75% of secondary GBM than in primary GBMs (36%) ([http://www.iarc.fr/p53](http://www.iarc.fr/p53%20) and \[[@B29]\]). Moreover, *MGMT* methylation has been observed to be associated with *TP53*mutations in secondary GBMs.

3. Cancer Epigenetics and Disrupted CellularPathways by Methylation-Associated Events {#sec3}
=====================================================================================

Epigenetic alterations have been linked with all cancer types. The spectrum of lesions includes gain and loss of DNA methylation including multicopy elements as well as single-copy genes. Most of these aberrations, mainly those followed on DNA methylation and deacetylation of histones, change gene expression and genome stability through regulation of local chromatin structure. Moreover, recent data suggest that early epigenetic changes occur during tumorigenesis and that they may predispose progenitor cells to further molecular changes that are involved in tumor promotion \[[@B35], [@B36]\]. Given the high frequency of DNA methylation changes, these events may become ideal biomarkers for early molecular diagnostics, such as *MGMT*, which has been observed to be hypermethylated in low-grade gliomas (grade II) further evolving to gliomas grade III and GBM \[[@B37]\]. Furthermore, this biomarker allows neurooncologists to predict patient\'s response to current chemotherapy with temozolomide \[[@B6]\].

Cancer cells change their methylation pattern in a wide-ranging manner. For instance, the regulation of methylating DNA methyltransferases 1, 3A, and 3B is altered profoundly. Moreover, there is a global DNA hypomethylation through demethylation of the promoters of a wide variety of genes as well as a severe hypermethylation that locally affects normally unmethylated regions, mainly CpG islands. As a rule, densely methylated DNA is associated with deacetylated histones and compacted chromatin, which is refractory to gene transcription ([Figure 3](#fig3){ref-type="fig"}) \[[@B38], [@B39]\]. DNA epigenetic alterations without gene mutations have been found to be common events in the pathogenesis of a wide variety of cancers, including gliomas, especially the methylation-associated silencing of tumor suppressor genes such as *VHL, p*16^INK4a^, *E-cadherin, hMLH1, BRCA1*, and *LKB1* \[[@B40], [@B41]\]. Promoter hypermethylation has been observed in a large number of regulator genes in tumor pathogenesis, including *p*15^INK4b^ (hypermethylated in hematological malignancies), *p73* (hypermethylated in lymphomas) and *ER* (receptor for estrogen-induced transcriptional activation), the DNA repair genes *MGMT*and*GSTP1* (related to the prevention of oxidative DNA damage), *TIMP3* and *DAPK1*\[[@B42]--[@B44]\].

An overview of disrupted cellular pathways in gliomas by hypo/hypermethylation of gene promoters or histone modifications is provided in [Table 1](#tab1){ref-type="table"}.

3.1. Mutator Pathways {#sec3.1}
---------------------

### 3.1.1. DNA Mismatch Repair System {#sec3.1.1}

Genomic instability plays a fundamental role in the pathogenesis of a wide variety of solid cancers \[[@B45], [@B46]\]. One form is the chromosomal instability (CIN), characterized by multiple gains and losses at specific chromosome regions \[[@B45]\]. In GBM, CIN has been found to be related with two pathways, typically harboring either mutations of *TP53* or amplification of the *EGFR* oncogene. A second form of genomic instability is the microsatellite instability (MSI), which typically displays length mutations at microsatellite sequences in noncoding and in coding regions of genes such as *PTEN, TGFßR-II, IGFIIR*, and *BAX* \[[@B47]--[@B50]\]. MSI is the consequence of the inactivation of genes driving the DNA mismatch repair system \[[@B47], [@B48], [@B51]\] and has previously been observed in hereditary syndromes, such as the hereditary nonpolyposis colorectal cancer (HNPCC) with a frequency up to 90% \[[@B48], [@B51]\]. In these cases, the defect is attributed to germ line mutations in mismatch repair genes, mainly *MLH1* and *MSH2*. However, in sporadic malignancies, MSI without mutations of those genes could be identified in colorectal (15%), nonsmall cell lung (35%), head and neck (28%), gastric (10%), and prostate cancers (8.5%) \[[@B52]--[@B56]\]. In GBM, MSI has been detected as well, with frequencies ranging from 5--50% \[[@B57]\]. Remarkably, in these sporadic tumors, MSI was not associated to mutations of the mismatch repair system but to *MLH1* promoter hypermethylation-mediated silencing. Interestingly, MSI was observed to be more frequent in those GBMs evolving from less malignant gliomas grade II or III, which typically display *TP53* mutations without *EGFR* amplification, as well as in relapse GBM \[[@B57]\]. Taking this into consideration, inactivation of tumor suppressor genes may represent the final stage in the malignant transformation of cells which are driven by an increasing genomic instability through the early inactivation of the DNA mismatch repair gene *MLH1.*

### 3.1.2. *MGMT*DNA Repair Gene {#sec3.1.2}

*MGMT* is another relevant example of a DNA repair regulator gene undergoing methylation-mediated inactivation in gliomas, even in an early phase*.MGMT* hypermethylation has been reported in gliomas grade I to IV from 20 to 90% depending on the histological subtype \[[@B58]\]. It removes mutagenic and cytotoxic adducts from O^6^-guanine in DNA ([Figure 4](#fig4){ref-type="fig"}). Alkylation of DNA at the O^6^ position of guanine is a primordial step in tumor formation, primarily due to the tendency of the O^6^-methylguanine to mispair with thymine during DNA replication, leading to the conversion of guanine-cytosine to adenine-thymine pairs in DNA. Furthermore, most common mutations caused by alkylating drugs are G : C to A : T transitions. A functioning *MGMT* provides cells protection against these sequence alterations, by transferring the alkyl group from the O^6^-guanine in DNA to an active cysteine within its own sequence \[[@B59]\]. *MGMT*-silenced cancer cells acquire a mutator phenotype through generation of transition point mutations of genes such as *TP53* or the oncogene *K-ras* \[[@B60]\]. Strikingly, *MGMT* hypermethylation has been observed to be associated with *TP53*mutations in secondary GBMs. Notably, these *TP53* mutations were almost exclusively G : C to A : T transition mutations and of those, most of them were at CpG sites (<http://www.iarc.fr/p53> and \[[@B29]\]).

A link was observed in GBM between *MGMT* promoter methylation and a hypermutator phenotype as a consequence of a mismatch repair deficiency in treated glioblastomas, a finding with potentially significant clinical implications \[[@B61]\].

### 3.1.3. Chromosomal Instability through Inactivation of *RECQL2* Helicase (*WRN* Gene) {#sec3.1.3}

Mutations in the Werner syndrome (WS) gene (*WRN*) are found in patients exhibiting the clinical features of this rare autosomal recessive disease, displaying premature onset of age-related pathologies \[[@B62]\]. Most of *WRN* mutations lead to loss of function of the protein \[[@B62]\]. The *WRN* gene belongs to the RecQ family of DNA helicases, whose mutations lead to defects in DNA replication, recombination, and repair. Since patients with *WRN* gene germ line mutations develop a wide variety of epithelial and mesenchymal tumors, a tumor suppressor function for *WRN* is anticipated and it is supported by the very frequent loss of heterozygosity at the chromosomal *WRN* region, 8p11.2--p12 in different cancers \[[@B64]\]. Nevertheless, somatic mutations of *WRN* gene have not been found in sporadic malignancies, but epigenetic-mediated silencing was reported in many tumor types of epithelial and mesenchymal lineage in a parallel way observed in *MLH1* \[[@B65]\]. The hypothesis defending the link between the methylation-mediated inactivation of *WRN* and a mutator phenotype in human malignancies is supported by the observation that *WRN* defective cancer cells through methylation are very sensitive to the action of DNA-damaging agents \[[@B65]\]. The significance of methylation of *WRN* in gliomas of different lineages and malignancy grades is a topic which remains to be definitively delineated and might have implications in survival prediction or response to chemotherapy.

3.2. Apoptosis {#sec3.2}
--------------

Current anticancer therapy is directed to activate the mitochondria-dependent or intrinsic apoptotic pathway, which will be stimulated by DNA damage induced by radiotherapy or drugs \[[@B66]\]. The success rate of this treatment modality in GBM, with very few exceptions, is actually low. This therapy failure may be in part explained by the apoptosis-resistant phenotype of GBM, an extended hallmark in cancer \[[@B67]\].

Epigenetic inactivation of apoptosis-related genes has been consistently reported in gliomas, such as *TMS1/ASC* and *DAPK1* \[[@B68], [@B69]\], *WIF-1* \[[@B70]\], *SFRP1* \[[@B71]\]. and *CASP8*\[[@B72]\], Previously. we have observed an epigenetic silencing of the proapoptotic gene *CASP8*during progression of primary-to-recurrent GBM \[[@B72]\]. *CASP8*is also hypermethylated in 40% of neuroblastomas and medulloblastomas, and a high concordance between gene methylation and protein expression was observed as well \[[@B73], [@B74]\]. *CASP8* encodes a protein at the top of the mitochondria-independent apoptosis cascade in a pathway triggered by ligation of death receptors, such as Fas and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptors (DR4 and DR5), by their cognate ligands \[[@B75], [@B76]\]. Once activated *CASP8*, the executioner *CASP3* becomes activated as well, which leads to dismantling of the cell. *CASP8* can also promote the activation of downstream caspases through proteolysis of BID (BH3-interacting domain death agonist protein) \[[@B77]\]. TRAIL (like tumor necrosis factor, TNF, and Fas ligand) is a potent inducer of apoptosis, and it is counteracted by the decoy receptors DcR-1 and 2. Because of the preferential expression of these antagonistic receptors in normal tissues, it was postulated that both protect from TRAIL-induced apoptosis \[[@B78]\]. Taking this into consideration, the main epigenetic deregulation point of the extrinsic apoptosis cascade in gliomas probably involves *CASP8*and the death receptors.

3.3. *TP53* and Cell Cycle Networks {#sec3.3}
-----------------------------------

The *TP53* gene encodes a protein displaying key roles in different substantial processes such as cell cycle, response to DNA damage, cell cycle, cell differentiation, and cell death \[[@B79]\]. Not only the function of *TP53* may result altered by mutations, but also it may result from alterations in *MDM2*,*MDM4*, or *CDKN2A*. At least two isoforms of the protein *MDM2* may interact with *TP53*, and it binds to wild-type and mutant *TP53*, thus inhibiting the ability of wild-type *TP53* to activate transcription from promoter sequences. In normal cells, there is a regulatory feed-back loop since the transcription of *MDM2* can be induced by wild-type *TP53*. In this way, the activity of *TP53* and the expression of *MDM2*are closely related. Inactivation of *TP53*in gliomas occurs preferentially in low-grade astrocytomas and secondary glioblastomas (about 65%) \[[@B1]\]. But inactivation of *TP53* without mutations is also reached by overexpression of *MDM2*. Another relevant player in *TP53*pathway is 14^ARF^, which binds to *MDM2* and inhibits *MDM2*-mediated *TP53* degradation. Hereby, there also is a feed-back regulatory loop since *p*14^ARF^ is negatively regulated by *TP53.* Hypermethylation of *CDKN2A* has been frequently observed in low-grade astrocytomas and secondary GBM in about 30% \[[@B80]\] but also in primary GBM in about 50% of the cases. In this regard, the TCGA project has observed alterations in the *TP53/MDM2*/*CDKN2A* pathway in about 87% of investigated GBM \[[@B61]\].

The cell cycle pathway *CDK4/CDKN2A/RB1* has been found to be disrupted in about 78% of GBM analyzed \[[@B61]\]. The RB1 protein executes the check point G1 into the S phase of the cell cycle. The *CDK4*/cyclin D1 complex induces the activation of the transcription factor E2F through phosphorylation of the RB1 protein, thus activating genes implicated in the cell cycle step G1 → S ([Figure 2](#fig2){ref-type="fig"}). On the other hand, *CDKN2A*inhibits the *CDK4*/cyclin D1 complex and, in this way, the transition G1 → S. Hypermethylation-mediated silencing of *RB1* and *CDKN2A*has been frequently observed in primary glioma tissues \[[@B81], [@B82]\].

3.4. Noncoding RNAs {#sec3.4}
-------------------

MicroRNAs (miRNAs) are small, 20--22-nucleotide noncoding RNAs that have been observed to be encoded by the genome of most of the eukaryotes examined so far. These small molecules have rapidly taken center stage as regulators of gene expression. Recent studies have identified important roles for miRNAs in the development of human cancers; about 200 of them have been associated with the lineage and differentiation of tumor cells, which implies that miRNA levels are crucial to tumor development \[[@B83]\]. Clusters of miRNAs have the properties of classic oncogenes and modulate and are modulated by the activities of other oncogenes \[[@B84]\].

In general, DNA hypomethylation induces a release of miRNA silencing in cancer cells as previously described \[[@B85]\]. One of the miRNA targets is miRNA-124a, which undergoes transcriptional inactivation by CpG island methylation in different human malignancies, in a similar way to that observed with tumor suppressor genes; in particular, a link was observed between the epigenetically mediated loss of function of miRNA-124a with the activation of the oncogenic factor cyclin D kinase 6 as well as the phosphorylation of the tumor suppressor gene*RB1*.

In GBM, molecular analyses have shown that miR-21 has the greatest differential elevated expression in human GBM biopsies, in primary cultures and GBM cell lines compared to those in nonneoplastic fetal and adult brain tissues \[[@B86], [@B87]\]. Targets implicated in the pathway of miR-21 include *TP53*,*TGF-ß*, the mitochondrial apoptotic pathway, and the tumor suppressor gene *PTEN* \[[@B88]\]. Moreover, knockdown of miR-21 in cultured GBM cells led to increased apoptotic cell death \[[@B86]\]. These findings pinpointed that aberrantly expressed miR-21 contributes to the malignant phenotype by inhibiting the expression of genes involved in apoptosis. Furthermore, miR-21 regulates different genes associated with migration and invasiveness in gliomas, including *RECK*, *TIMP3*, and inhibitors of matrix metalloproteinase. In contrast, downregulation of miR-21 in glioma cells leads to a reduction in their migratory and invasive capability \[[@B91]\].

The complexity of this scenario in GBM is further underscored by findings showing a very low expression of other miRNAs such as miR-124, miR-137, miR-7, and miR-128 \[[@B89], [@B90]\]. Furthermore, transfection of miRNA-124 or miRNA-137 also induced G1 cell cycle arrest in GBM cell lines, which was associated with decreased expression of cyclin-dependent kinase 6 and phosphorylated retinoblastoma proteins \[[@B90]\].

Altogether, increasing evidence exists that miRNAs regulate multiple pathways involved in GBM pathogenesis. For most of them, the mechanisms by which miRNAs become altered in GBM are only partially explained. Nevertheless, general regulatory mechanisms (hypermethylation, mutation, deletion, and amplification) are likely to be represented, as well as miRNA-specific mechanisms, for instance altered processing or degradation. But if we keep in mind that protein-coding genes represent about 2% of the whole genome and that noncoding genome regions probably are of unrecognised great importance for physiological tissue development and for disease conditions \[[@B92]\], it is easy to argue that other noncoding RNAs, for instance, transcribed ultraconserved regions, small nucleolar RNAs, PIWI-interacting RNAs, large intergenic noncoding RNAs (lincRNAs) and the group of long noncoding RNAs, might also contribute to the development of human cancers \[[@B93]\]. It is anticipated that this total will become much higher in the near future as further key miRNA/target pairs are experimentally validated. The identification of these miRNAs and their methylation-induced inactivation will create opportunities for new therapeutic strategies by modifying chemoresistance or by inducing sensitivity to radiotherapy.

4. Epigenomics: The New Venue in GliomaPathogenesis {#sec4}
===================================================

Summarizing the reviewed issues, hypermethylation of CpG islands gene promoters is only the tip of the iceberg in the complex context of epigenetic mechanisms contributing to GBM onset. Unraveling the epigenetic lesions in malignant gliomas will open up possibilities for discovering new biomarkers for brain tumor detection and prognosis, as reached with prostate cancer. Restoring epigenetically altered pathways will probably lead to the development of new therapeutic tools with translational significance. We are entering into a new time of personalized molecular treatment, which will allow a successful crosstalk between the lab bench and patient bed, based on a better understanding of genetic and epigenetic mechanisms of human cancers.

![(a)   T1-weighted, gadolinium-enhanced axial MRI showing the resection hole one day after surgical extirpation of a right frontal glioblastoma multiforme (1). Four months after surgery, fractionated radiotherapy (59 Gy), and chemotherapy with temozolomide, a new right periventricular tumor manifestation was observed invading the basal ganglia. An enhancement in the dorsal resection hole is evidenced, also indicating the local relapse (2). MRI gently provided by Professor A. Giese (Department of Neurosurgery, University of Mainz, Germany). (b) T1-weighted, gadolinium-enhanced axial MRI revealing a large left frontal glioblastoma. The illustration depicts the outer tumor border (as defined by the gadolinium enhancement) with glioblastoma cells migrating far away through the brain tissue.](JST2012-519807.001){#fig1}

![*TP53*/*MDM2*/p14^ARF^ and cell cycle p16^INK4a^/*CDK4*/*RB1* networks and targets of hypermethylation-mediated inactivation (marked by red stocks).](JST2012-519807.002){#fig2}

![(a) 3D MRI. Normal glial cells CpG islands in the promoter regions of genes lack of methylation, which is a prerequisite for active gene transcription. Fully methylated CpG islands are found only in the promoters of silenced alleles for selected imprinted autosomal genes and silenced genes on the inactivated X-chromosomes of females. (b) 3D MRI showing a right frontal GBM, in which cells change their methylation pattern in a wide manner including deregulation of methylating DNA methyl-transferases 1, 3A, and 3B, global hypomethylation through demethylation in CpG islands of the promoters of a wide variety of genes as well as a severe hypermethylation locally affecting unmethylated regions. Densely methylated DNA is associated with deacetylated histones and compacted chromatin, which is refractory to gene transcription.](JST2012-519807.003){#fig3}

![Diagram showing how alkylating drugs temozolomide (TMZ), nimustine (ACNU), and carmustine (BCNU) act damaging DNA by introducing alkyl residues in the O^6^ position of guanine, thus producing DNA interstrand cross-links. The DNA repair O^6^-methylguanine DNA methyltransferase (*MGMT*) reverses the formation of adducts at the O^6^ position of guanine. MGMT transfers the alkyl group from the O^6^-guanine to an active cysteine within its own sequence in a reaction that inactivates one MGMT molecule for each lesion repaired. The alkylated MGMT protein then becomes detached from DNA and is targeted for degradation by ubiquitination.](JST2012-519807.004){#fig4}

###### 

Cellular pathways deregulated in gliomas and associated epigenetic events through promoter hypermethylation, CpGs hypomethylation, and histone alterations leading to modified chromatin states.

  Cellular pathway               Genes in gliomas deregulated by hypo/hypermethylation/histone modification
  ------------------------------ ----------------------------------------------------------------------------
  Ras signaling                  RASSF1A, RRP22, DIRAS3
  Cell migration and adherence   NECL1, E-cadherin, SLIT2, EMP3, TIMP3
  Wnt signaling                  WIF1, FZD9, IGFBP-3, SFRP family, PEG3
  Tyrosine kinase pathways       KIT, SYK, c-ROS
  Transcription factors          SOX2, KLF4, GATA 6, ATOH1
  Homeobox genes                 HOXA 9, HOXA10, HOXA11
  Sonic hedgehog signaling       PTCH1, Cyclin D2, Plakoglobin, PAX6, NKX2.2
  Notch signalling               NEURL1, HES1, HEY1
  BMP developmental pathway      BMPR1B
  Hypermutator pathways          hMLH1, hPMS2, MGMT, WRN
  Apoptosis                      TMS1, DAPK1, CASP8, DR4, DR5
  TP53/cell cycle                HIC-1, CDKN2A, RB1, p16^INK4a^
  MicroRNAs                      miR-124a, miR-21, miR-7, miR-137, miR128
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